ReviewGuideline/Fact SheetDiabetes Metab J 2023;47:1-9https::/doi.org/10.4093/dmj.2022.0448dmpISSN2233-6079,eISSN2233-6087DIABETES METABOLISM JOURNAL间Check for updatesLipid Management in Korean People with Type 2Diabetes Mellitus:Korean Diabetes Association andKorean Society of Lipid and Atherosclerosis ConsensusStatementYe Seul Yang',Hack-Lyoung Kim2,Sang-Hyun Kim2,Min Kyong Moon,on Behalf of Committee of Clinical PracticeGuideline,Korean Diabetes Association and Clinical Practice Guideline Committee,Korean Society of Lipid andAtherosclerosis'Department of Medicine,Seoul National University College of Medicine,Seoul,Department of Internal Medicine,Seoul Metropolitan Gover nment Seoul National University Boramae Medical Center,Seoul,Department ofInternal Medicine,Seoul National University College of Medicine Seoul,KoreaDyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease(CVD).Although the primary treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol(LDL-C),achiev-ing this goal remains suboptimal according to recent studies.It is important to set the target goal for LDL-C control based on anaccurate risk assessment for CVD.Here,we summarize the latest evidence on lipid management in patients with diabetes andpresent a consensus of the Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis on the treatment goalsof LDL-C according to the duration of diabetes,presence of CVD,target organ damage,or major cardiovascular risk factors.Inpatients with type 2 diabetes mellitus(T2DM)and CVD,an LDL-C goal of <55 mg/dL and a reduction in LDL-Clevel by 50%ormore from the baseline is recommended.For the primary prevention of CVD in patients with T2DM with a duration of diabetes210 years,major cardiovascular risk factors,or target organ damage,an LDL-C goal of <70 mg/dL is recommended.In patientswith T2DM with a duration of diabetes <10 years and no major cardiovascular risk factors,an LDL-C goal of <100 mg/dL is rec-ommendedKeywords:Cholesterol,LDL;Diabetes mellitus,type 2;Dyslipidemias;Guideline;Hydroxymethylglutaryl-CoA reductase in-hibitorsINTRODUCTIONpatients with diabetes mellitus,although cardiovascular com-plications and death from CVD have recently been decreasingCardiovascular disease (CVD)is the leading cause of death in[1].Dyslipidemia in patients with diabetes is an importantCorresponding authors:Min Kyong Moon htps//orcidor/0-0002-560-2846This is an Open Access article distributed under the terms of the Creative CommonsDivision of Endocrinology and Metabolism,Department of Internal Medicine,SeoulAttribution Non-Commercial License (https//creativecommonsorg/licenses/by-nc/4.0/)Metropolitan Government Seoul National University Boramae Medical Center,Seoulwhich pe rmits unrestricted non-commerc ial use,distribution,and reproduction in amyNational University College of Medicine,20 Boramae-ro 5-gil,Dongjak-gu,Seoul07061,medium.provi
